Oncimmune Overview

  • Founded
  • 2002
Founded
  • Status
  • Public
  • Employees
  • 47
Employees
  • Stock Symbol
  • ONC
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $1.13
  • (As of Friday Closing)

Oncimmune General Information

Description

Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes Early CDT Lung and ImmunoINSIGHTS.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Stock Exchange
LON
Primary Office
  • MediCity - D6 Building
  • 1 Thane Road
  • Nottingham NG90 6BH
  • England, United Kingdom
+44 0115 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncimmune Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.13 $1.17 $1.08 - $3.12 $78.3M 69.5M 55.6K -$0.14

Oncimmune Financials Summary

In Thousands,
USD
TTM 30-Nov-2021 FY 2021 31-May-2021 FY 2020 31-May-2020 FY 2019 31-May-2019
EV 158,083 213,954 87,838 62,204
Revenue 4,575 4,957 642 222
EBITDA (8,142) (5,490) (11,445) (10,848)
Net Income (9,487) (6,164) (10,662) (10,409)
Total Assets 24,206 34,424 12,732 11,891
Total Debt 11,123 13,425 10,215 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oncimmune Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncimmune‘s full profile, request access.

Request a free trial

Oncimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialis
Biotechnology
Nottingham, United Kingdom
47 As of 2021
00000
000000 - 000

00000

am, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute iru
0000000000000
Rockville, MD
00 As of 0000
00000
000000000 00000

00000000

co laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupt
000000000 00000 (0000000000)
Baltimore, MD
000 As of 0000
00000
0000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oncimmune Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OpGen Formerly VC-backed Rockville, MD 00 00000 000000000 00000
00000000 000000 00 Formerly VC-backed Baltimore, MD 000 00000 000000&0 00000
0-00-000 Formerly VC-backed Concord, MA 00 000.00 000000&0 000.00
You’re viewing 3 of 3 competitors. Get the full list »

Oncimmune Patents

Oncimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201619954-D0 Antibody assay Ceased 25-Nov-2016 000000000000
US-20190376975-A1 Antibody assay Pending 25-Nov-2016 000000000000
JP-2020515826-A Antibody assay Pending 25-Nov-2016 000000000000
CA-3044492-A1 Antibody assay Pending 25-Nov-2016 000000000000
AU-2017365931-A1 Antibody assay Abandoned 25-Nov-2016 G01N33/57438
To view Oncimmune’s complete patent history, request access »

Oncimmune Executive Team (12)

Name Title Board Seat Contact Info
Adam Hill Ph.D Chief Executive Officer & Board Member
Matthew Hall Chief Financial Officer, Finance & Board Member
Matthew Hall Chief Financial Officer
Cameron Barnard Chief Business Officer
Matthew Luttrell Chief Commercial Officer
You’re viewing 5 of 12 executive team members. Get the full list »

Oncimmune Board Members (12)

Name Representing Role Since
Adam Hill Ph.D Oncimmune Chief Executive Officer & Board Member 000 0000
Annalisa Jenkins Self Board Member 000 0000
Matthew Hall Oncimmune Chief Financial Officer, Finance & Board Member 000 0000
Meinhard Schmidt Self Non Executive Chairman 000 0000
Sören Thestrup-Nielsen MD Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Oncimmune Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncimmune Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oncimmune‘s full profile, request access.

Request a free trial

Oncimmune Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 19-Mar-2019 0000000000 00.000 Diagnostic Equipment 0000 0000
Central Medical Laboratory 24-Sep-2015 Merger/Acquisition Other Healthcare Services
To view Oncimmune’s complete acquisitions history, request access »

Oncimmune Subsidiaries (1)

Company Name Industry Location Founded
00000000 000000000 Diagnostic Equipment Dortmund, Germany 0000
To view Oncimmune’s complete subsidiaries history, request access »